Watching Silexion Therapeutics Corp? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planSilexion Therapeutics Corp
silexion.comAI Executive Summary
AI-powered analysis of 8-K filing content
Silexion Therapeutics announced the initiation of a Phase 2/3 clinical trial for SIL204 targeting locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center on July 29, 2026. This milestone advances the company's oncology portfolio in an area of high unmet medical need and may strengthen investor confidence.
Key Takeaways
Phase 2/3 clinical trial for SIL204 has been successfully initiated for locally advanced pancreatic cancer treatment
Trial is being conducted at Tel Aviv Sourasky Medical Center, indicating international clinical development infrastructure
2 more takeaways
Related Filings (1)
1 more filing from Silexion Therapeutics Corp in the last 90 days
Filing Overview
What This Means
Silexion Therapeutics Corp filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.